[{"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-001", "question": "A 52-year-old man with primary sclerosing cholangitis and ulcerative colitis maintained on vedolizumab presents with progressive jaundice, pruritus, and weight loss over 3 months. MRCP shows a dominant stricture at the hepatic hilum with intrahepatic ductal dilation. CA 19-9 is 180 U/mL. Brush cytology from ERCP is suspicious but not diagnostic for malignancy. PET-CT shows FDG avidity at the stricture with standardized uptake value (SUV) max of 6.2. Which of the following is the most appropriate next step in management?", "options": ["Proceed directly to liver transplantation without biopsy confirmation given high suspicion for cholangiocarcinoma in PSC", "Perform endoscopic ultrasound with fine-needle aspiration of the hilar mass", "Initiate neoadjuvant chemoradiation followed by liver transplantation per Mayo Clinic protocol", "Repeat ERCP with cholangioscopy and targeted biopsies of the suspicious area", "Treat as benign dominant stricture with serial stenting and repeat CA 19-9 in 3 months"], "answer": "C", "answer_index": 2, "explanation": "In patients with PSC and suspected hilar cholangiocarcinoma, the Mayo Clinic protocol for neoadjuvant chemoradiation followed by liver transplantation requires strict diagnostic criteria including biopsy confirmation or strongly suggestive findings (CA 19-9 >100 U/mL, malignant-appearing stricture on imaging). PET SUV >5.0 with suspicious cytology meets criteria for protocol enrollment. Direct transplantation without protocol adherence risks transplanting unrecognized metastatic disease. Cholangioscopy and EUS-FNA have higher risks of peritoneal seeding in potentially resectable/transplantable cases.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: Correct best answer. The vignette presents a classic scenario of suspected cholangiocarcinoma (CCA) in a patient with primary sclerosing cholangitis (PSC). Key clues include the dominant stricture, CA 19-9 > 100 U/mL (180), and suspicious cytology. These findings meet the clinical criteria for the Mayo Clinic Protocol for liver transplantation in CCA, which allows for enrollment without definitive tissue diagnosis to avoid the risk of tumor seeding associated with percutaneous or transperitoneal biopsy. Option C correctly identifies the standard of care: neoadjuvant chemoradiation followed by transplantation. Option A is incorrect because direct transplantation has high recurrence rates. Option B (EUS-FNA) is contraindicated in transplant candidates due to the risk of peritoneal seeding. Option D (repeat ERCP) is less appropriate because the patient already meets the criteria for the protocol based on the provided data (stricture + elevated marker + suspicious cytology + PET avidity), and further delay for biopsy is unnecessary and potentially risky if it delays therapy. Option E is unsafe given the high probability of malignancy.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Correct best answer. The vignette presents a classic scenario of suspected cholangiocarcinoma (CCA) in a patient with primary sclerosing cholangitis (PSC). Key clues include the dominant stricture, CA 19-9 > 100 U/mL (180), and suspicious cytology. These findings meet the clinical criteria for the Mayo Clinic Protocol for liver transplantation in CCA, which allows for enrollment without definitive tissue diagnosis to avoid the risk of tumor seeding associated with percutaneous or transperitoneal biopsy. Option C correctly identifies the standard of care: neoadjuvant chemoradiation followed by transplantation. Option A is incorrect because direct transplantation has high recurrence rates. Option B (EUS-FNA) is contraindicated in transplant candidates due to the risk of peritoneal seeding. Option D (repeat ERCP) is less appropriate because the patient already meets the criteria for the protocol based on the provided data (stricture + elevated marker + suspicious cytology + PET avidity), and further delay for biopsy is unnecessary and potentially risky if it delays therapy. Option E is unsafe given the high probability of malignancy.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-002", "question": "A 38-year-old woman with paroxysmal nocturnal hemoglobinuria (PNH) on eculizumab for 5 years presents with fatigue and dark urine. Laboratory studies show hemoglobin 7.2 g/dL (baseline 10.5), LDH 850 U/L (baseline 300), haptoglobin <10 mg/dL, and negative direct antiglobulin test. She received her last eculizumab dose 12 days ago. Peripheral blood flow cytometry shows 95% PNH clone size (granulocytes). Complement C5 level is undetectable. Which of the following is the most likely explanation for her breakthrough hemolysis?", "options": ["Development of anti-eculizumab antibodies causing drug neutralization", "C5 gene polymorphism (c.2654G→A) resulting in eculizumab-resistant C5", "Concurrent mycoplasma pneumoniae infection with cold agglutinin production", "Functional deficiency of complement factor H due to acquired mutation", "Proximal complement pathway activation via C3 convertase amplification"], "answer": "B", "answer_index": 1, "explanation": "The c.2654G→A polymorphism in the C5 gene results in a single amino acid change (p.Arg885His) that prevents eculizumab binding while maintaining C5 function, leading to breakthrough hemolysis despite adequate drug levels. This autosomal dominant mutation affects approximately 3-4% of Japanese patients and requires switching to ravulizumab or other anti-C5 agents. Anti-drug antibodies are rare with eculizumab. Mycoplasma would cause cold agglutinin disease with positive DAT. Factor H deficiency causes atypical HUS, not PNH exacerbation.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: N (No answer defensible). The vignette describes a patient with PNH who has been successfully treated with eculizumab for 5 years (baseline LDH 300, Hb 10.5) now presenting with breakthrough intravascular hemolysis (dark urine, LDH 850). The keyed answer (B, C5 polymorphism) refers to a germline mutation (p.Arg885His) that prevents eculizumab binding. This mutation causes primary non-response from the first dose; it is medically impossible for a patient to have 5 years of good response and then 'develop' a germline polymorphism causing breakthrough. Furthermore, the stem states 'Complement C5 level is undetectable.' If C5 is absent, C5-dependent intravascular hemolysis cannot occur (contradiction). If the author meant 'Free C5 is undetectable' (indicating effective drug binding), then hemolysis should be controlled. Option E (proximal pathway) causes extravascular hemolysis and is typically DAT-positive (stem says DAT-negative). Option A (antibodies) would lead to high free C5, contradicting the lab. Thus, the clinical history and lab data mutually exclude all options.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: N (No answer defensible). The vignette describes a patient with PNH who has been successfully treated with eculizumab for 5 years (baseline LDH 300, Hb 10.5) now presenting with breakthrough intravascular hemolysis (dark urine, LDH 850). The keyed answer (B, C5 polymorphism) refers to a germline mutation (p.Arg885His) that prevents eculizumab binding. This mutation causes primary non-response from the first dose; it is medically impossible for a patient to have 5 years of good response and then 'develop' a germline polymorphism causing breakthrough. Furthermore, the stem states 'Complement C5 level is undetectable.' If C5 is absent, C5-dependent intravascular hemolysis cannot occur (contradiction). If the author meant 'Free C5 is undetectable' (indicating effective drug binding), then hemolysis should be controlled. Option E (proximal pathway) causes extravascular hemolysis and is typically DAT-positive (stem says DAT-negative). Option A (antibodies) would lead to high free C5, contradicting the lab. Thus, the clinical history and lab data mutually exclude all options.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-003", "question": "A 67-year-old man who underwent orthotopic liver transplantation 4 months ago for HCV cirrhosis presents with fever, cough, and hypoxemia. He is on tacrolimus and prednisone 5 mg daily. Chest CT shows multiple nodular opacities with surrounding ground-glass halos. Bronchoalveolar lavage PCR is positive for Torque teno virus (TTV) DNA at 10^8 copies/mL. Blood TTV viral load is 10^7 copies/mL. Which of the following is the most appropriate interpretation and management?", "options": ["TTV indicates severe immunosuppression; reduce tacrolimus dose and monitor for resolution", "TTV is a direct pulmonary pathogen; initiate intravenous ribavirin therapy", "TTV reactivation suggests CMV co-infection; start ganciclovir empirically", "TTV viral load has no clinical significance in this setting; pursue alternative diagnoses", "TTV indicates possible donor-derived infection; perform lung biopsy for histopathology"], "answer": "A", "answer_index": 0, "explanation": "Torque teno virus (TTV) viral load serves as a functional biomarker of overall immunosuppression in transplant recipients, with high levels indicating excessive immunosuppression and increased risk of opportunistic infections. The radiographic findings suggest invasive fungal infection (e.g., aspergillosis) in an over-immunosuppressed host. Reducing immunosuppression while evaluating for fungal pathogens is appropriate. TTV itself is not a pulmonary pathogen. There is no established antiviral therapy for TTV, and it does not specifically indicate CMV co-infection or donor-derived infection.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The question tests the clinical interpretation of Torque teno virus (TTV) viral load in solid organ transplant recipients. TTV is a ubiquitous anellovirus considered non-pathogenic in humans; however, its viral load serves as a surrogate marker for the net state of immunosuppression. High TTV loads correlate with over-immunosuppression and an increased risk of opportunistic infections, while low loads correlate with rejection risk. The clinical vignette describes a patient with radiographic findings highly suggestive of invasive pulmonary aspergillosis (nodules with halo sign). Option A correctly identifies that high TTV indicates severe immunosuppression and suggests reducing tacrolimus, which is the correct strategic response to over-immunosuppression in the setting of infection. Options B and C are incorrect because TTV is not a direct pulmonary pathogen and does not require antiviral therapy. Option D is incorrect because TTV does have clinical significance as a biomarker. While Option A's management instruction ('monitor for resolution') is clinically incomplete—as the patient likely requires antifungal therapy for aspergillosis—it is the only option that correctly interprets the TTV data. Therefore, A is the unique best answer.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The question tests the clinical interpretation of Torque teno virus (TTV) viral load in solid organ transplant recipients. TTV is a ubiquitous anellovirus considered non-pathogenic in humans; however, its viral load serves as a surrogate marker for the net state of immunosuppression. High TTV loads correlate with over-immunosuppression and an increased risk of opportunistic infections, while low loads correlate with rejection risk. The clinical vignette describes a patient with radiographic findings highly suggestive of invasive pulmonary aspergillosis (nodules with halo sign). Option A correctly identifies that high TTV indicates severe immunosuppression and suggests reducing tacrolimus, which is the correct strategic response to over-immunosuppression in the setting of infection. Options B and C are incorrect because TTV is not a direct pulmonary pathogen and does not require antiviral therapy. Option D is incorrect because TTV does have clinical significance as a biomarker. While Option A's management instruction ('monitor for resolution') is clinically incomplete—as the patient likely requires antifungal therapy for aspergillosis—it is the only option that correctly interprets the TTV data. Therefore, A is the unique best answer.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-004", "question": "A 44-year-old woman with autoimmune hepatitis-primary biliary cholangitis overlap syndrome on ursodeoxycholic acid and budesonide develops recurrent episodes of severe, cramping abdominal pain with diarrhea occurring 30-60 minutes after meals. Symptoms improve with fasting. CT angiography shows no mesenteric ischemia. Gastric emptying study is normal. Upper endoscopy with duodenal biopsies shows villous blunting and intraepithelial lymphocytes. Serum tryptase during an episode is 45 ng/mL (normal <11.4). Which of the following is the most likely diagnosis?", "options": ["Mesenteric venous thrombosis with portal hypertensive enteropathy", "Systemic mastocytosis with gastrointestinal involvement", "Celiac disease with refractory sprue", "Abdominal angina from median arcuate ligament syndrome", "Bile acid malabsorption due to ileal dysfunction"], "answer": "B", "answer_index": 1, "explanation": "Systemic mastocytosis can present with postprandial abdominal pain, diarrhea, and flushing due to mast cell mediator release triggered by food. Elevated serum tryptase (>20 ng/mL) during symptoms is diagnostic. The duodenal findings represent mast cell infiltration rather than celiac disease. Mesenteric ischemia was ruled out by CT angiography. Median arcuate ligament syndrome causes epigastric pain but not diarrhea or elevated tryptase. Bile acid malabsorption does not explain the elevated tryptase or timing of symptoms.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V (Valid)\\nVerdict on keyed answer: Correct best\\n\\nThe item presents a clinical scenario where the key discriminator is the serum tryptase level of 45 ng/mL (normal <11.4). While the duodenal biopsy findings (villous blunting and intraepithelial lymphocytes) are the classic histologic description for Celiac disease (Choice C), Celiac disease does not explain a tryptase level of this magnitude. Systemic Mastocytosis (Choice B) is characterized by tryptase >20 ng/mL (a minor diagnostic criterion) and frequently involves the GI tract, causing abdominal pain and diarrhea triggered by food (mast cell mediator release). SM can also cause mucosal abnormalities including villous atrophy, mimicking Celiac disease. The other options (A, D, E) are ruled out by the CT findings or the elevated tryptase. The item correctly forces the examinee to prioritize the specific biomarker (tryptase) over the histologic distractor. The logic is sound and the medical facts are accurate for board-level testing.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid)\nVerdict on keyed answer: Correct best\n\nThe item presents a clinical scenario where the key discriminator is the serum tryptase level of 45 ng/mL (normal <11.4). While the duodenal biopsy findings (villous blunting and intraepithelial lymphocytes) are the classic histologic description for Celiac disease (Choice C), Celiac disease does not explain a tryptase level of this magnitude. Systemic Mastocytosis (Choice B) is characterized by tryptase >20 ng/mL (a minor diagnostic criterion) and frequently involves the GI tract, causing abdominal pain and diarrhea triggered by food (mast cell mediator release). SM can also cause mucosal abnormalities including villous atrophy, mimicking Celiac disease. The other options (A, D, E) are ruled out by the CT findings or the elevated tryptase. The item correctly forces the examinee to prioritize the specific biomarker (tryptase) over the histologic distractor. The logic is sound and the medical facts are accurate for board-level testing.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-005", "question": "A 62-year-old man with essential thrombocythemia (JAK2 V617F-positive) on hydroxyurea presents with acute onset of severe headache and right hemiparesis. CT head shows left middle cerebral artery territory infarction. Platelet count is 450,000/μL. MRI brain with contrast reveals multiple small enhancing lesions in both cerebral hemispheres. Transthoracic echocardiogram shows no vegetations. Blood cultures are negative. Which of the following is the most likely underlying mechanism for his stroke?", "options": ["Nonbacterial thrombotic endocarditis from hypercoagulable state", "Leukoencephalopathy from hydroxyurea toxicity", "Transformation to acute myeloid leukemia with CNS involvement", "Cerebral vasculitis secondary to JAK2 mutation", "Paradoxical embolism through patent foramen ovale"], "answer": "A", "answer_index": 0, "explanation": "Myeloproliferative neoplasms, particularly essential thrombocythemia, can cause nonbacterial thrombotic endocarditis (NBTE) with sterile vegetations that embolize to cerebral arteries. The multiple enhancing brain lesions represent septic emboli analogs from NBTE. Hydroxyurea leukoencephalopathy causes symmetric white matter changes without enhancing lesions. AML transformation would show blasts in blood or marrow. Cerebral vasculitis is not associated with JAK2 mutations. Paradoxical embolism would not explain multiple enhancing lesions without a venous source.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The question describes a patient with Essential Thrombocythemia (ET) presenting with an acute stroke and multiple brain lesions. The key discriminating features are the hypercoagulable state (JAK2+ ET), the pattern of 'multiple small enhancing lesions' in addition to a major vascular territory infarct (suggesting embolic showers of varying ages), and negative infectious workup (negative blood cultures). While TTE is negative, it has low sensitivity for vegetations; Nonbacterial Thrombotic Endocarditis (NBTE) is a known complication of hypercoagulable states and causes sterile vegetations that embolize, resulting in multiple infarcts. The 'enhancing' nature of the small lesions implies subacute ischemia (BBB breakdown) or inflammation, consistent with a stuttering embolic course. Option B is incorrect as hydroxyurea toxicity typically causes diffuse non-enhancing white matter changes. Option C is unlikely without blasts or cytopenias. Option D is not a standard association. Option E is less likely than NBTE because NBTE is a direct consequence of the systemic disease (hypercoagulability), whereas PFO is an anatomical coincidence requiring an unstated DVT. Thus, A is the only option that mechanistically links the systemic disease to the specific neuroimaging pattern via a known complication, despite the negative TTE (a common board distractor).\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The question describes a patient with Essential Thrombocythemia (ET) presenting with an acute stroke and multiple brain lesions. The key discriminating features are the hypercoagulable state (JAK2+ ET), the pattern of 'multiple small enhancing lesions' in addition to a major vascular territory infarct (suggesting embolic showers of varying ages), and negative infectious workup (negative blood cultures). While TTE is negative, it has low sensitivity for vegetations; Nonbacterial Thrombotic Endocarditis (NBTE) is a known complication of hypercoagulable states and causes sterile vegetations that embolize, resulting in multiple infarcts. The 'enhancing' nature of the small lesions implies subacute ischemia (BBB breakdown) or inflammation, consistent with a stuttering embolic course. Option B is incorrect as hydroxyurea toxicity typically causes diffuse non-enhancing white matter changes. Option C is unlikely without blasts or cytopenias. Option D is not a standard association. Option E is less likely than NBTE because NBTE is a direct consequence of the systemic disease (hypercoagulability), whereas PFO is an anatomical coincidence requiring an unstated DVT. Thus, A is the only option that mechanistically links the systemic disease to the specific neuroimaging pattern via a known complication, despite the negative TTE (a common board distractor).", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-006", "question": "A 31-year-old hematopoietic stem cell transplant recipient (day +45) for AML develops new-onset confusion and myoclonus. MRI brain shows symmetric T2 hyperintensities in the thalami and periaqueductal gray matter. CSF shows 5 WBCs/μL, protein 65 mg/dL, glucose 60 mg/dL (serum 95 mg/dL). CSF PCR for HSV, VZV, EBV, CMV, and HHV-6 are negative. Metagenomic next-generation sequencing of CSF detects Astrovirus VA1/HMO-C RNA. Which of the following is the most appropriate management?", "options": ["Intravenous immunoglobulin 2 g/kg divided over 2-5 days", "Oral nitazoxanide 500 mg twice daily for 14 days", "Reduce immunosuppression and provide supportive care", "Intravenous ribavirin loading dose 33 mg/kg then 16 mg/kg every 6 hours", "Intrathecal administration of foscarnet 40 mg twice weekly"], "answer": "C", "answer_index": 2, "explanation": "Astrovirus VA1/HMO-C encephalitis in immunocompromised hosts has no proven antiviral therapy. Reduction of immunosuppression to allow immune reconstitution is the mainstay of management, along with supportive care. Intravenous immunoglobulin has been used but lacks proven efficacy. Nitazoxanide has in vitro activity but no clinical data in CNS infections. Ribavirin has poor CNS penetration and no proven benefit. Intrathecal foscarnet is used for HSV/VZV encephalitis but not for astrovirus.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette describes a classic presentation of Astrovirus VA1/HMO-C encephalitis in a hematopoietic stem cell transplant recipient, confirmed by metagenomic sequencing. The MRI findings (thalamic and periaqueductal gray hyperintensities) and clinical symptoms (myoclonus, confusion) are highly characteristic. There are currently no FDA-approved antiviral therapies for astrovirus. Consequently, the standard of care and most appropriate management strategy involves the reduction of immunosuppression to facilitate immune reconstitution, which allows the host immune system to clear the infection. While IVIG (Option A) is often used adjunctively in case reports, it lacks proven efficacy and is secondary to the restoration of cellular immunity. Foscarnet (Option E) targets DNA polymerases and is ineffective against RNA viruses like astrovirus. Ribavirin and nitazoxanide (Options B and D) lack clinical evidence for CNS astrovirus infection. Therefore, Option C is the unique best answer, consistent with current transplant infectious disease principles.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes a classic presentation of Astrovirus VA1/HMO-C encephalitis in a hematopoietic stem cell transplant recipient, confirmed by metagenomic sequencing. The MRI findings (thalamic and periaqueductal gray hyperintensities) and clinical symptoms (myoclonus, confusion) are highly characteristic. There are currently no FDA-approved antiviral therapies for astrovirus. Consequently, the standard of care and most appropriate management strategy involves the reduction of immunosuppression to facilitate immune reconstitution, which allows the host immune system to clear the infection. While IVIG (Option A) is often used adjunctively in case reports, it lacks proven efficacy and is secondary to the restoration of cellular immunity. Foscarnet (Option E) targets DNA polymerases and is ineffective against RNA viruses like astrovirus. Ribavirin and nitazoxanide (Options B and D) lack clinical evidence for CNS astrovirus infection. Therefore, Option C is the unique best answer, consistent with current transplant infectious disease principles.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]